Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 8, 2008, Pages 982-983

  Fu, Ran ^a   Sun, Yan Ming ^a   Su, Ying ^a   Wu, Yun ^a   Luan, Ying ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductse inhibitor; Coronary heart disease; Genetic polymorphism; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTILIPEMIC AGENTS; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, HDL; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SIMVASTATIN;

EID: 46749102165     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04941.x     Document Type: Article

References (11)

1. Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: Continuing issues. Curr. Opin. Lipidol. 2004 15 : 261 7.
2. Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med. Hypotheses 2006 66 : 1019 21.
3. Alemao E, Yin D, Sintonen H, Salomaa V, Jousilahti P. Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: The National FINRISK Study. Am. J. Cardiovasc. Drugs 2006 6 : 207 10.
4. Thompson GR, O'Neill F, Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur. Heart J. 2002 23 : 200 6.
5. Christidis DS, Liberopoulos EN, Kakafika AI et al. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin. Arch. Med. Res. 2007 38 : 403 10.
6. Himbergen TM, van Tits LJ, Voorbij HA, de Graaf J, Stalenhoef AF, Roest M. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia. J. Intern. Med. 2005 258 : 442 9.
7. Yamane T, Matsumoto T, Nakae I et al. Impact of paraoxonase polymorphism (Q192R) on endothelial function in intact coronary circulation. Hypertens. Res. 2006 29 : 349 55.
8. Topcuoglu A, Uzun H, Aydin S et al. The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J. Exp. Med. 2005 1 : 79 86.
9. Kerkeni M, Addad F, Chauffert M et al. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin. Biochem. 2006 39 : 821 5.
10. Chen J, Chan W, Wallenstein S, Berkowitz G, Wetmur JG. Haplotype-phenotype relationships of paraoxonase-1. Cancer Epidemiol. Biomarkers Prev. 2005 14 : 731 4.
11. Bergheanu SC, Van Tol A, Dallinga-Thie GM et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr. Med. Res. Opin. 2007 23 : 2235 40.